AVATR TIMELINE - WHAT WE’VE ACHIEVED THUS FAR
It’s been an incredible journey for the Inavya team, and yet there are still so many more milestones we’re aiming for.
Here’s a brief snapshot of some of our proudest moments.
It’s been an incredible journey for the Inavya team, and yet there are still so many more milestones we’re aiming for.
Here’s a brief snapshot of some of our proudest moments.
Umberto Parini Hospital - training with doctors for starting the trial for CVDs and COVID-19 patients
AVATR starts the trial the University of Catanzaro for the MADCAP project (as part of the COVID-X EU project)
Frankfurt University Hospital - post-operation monitoring kick-off.
MADCAP project - trial at University of Catanzaro for CVDs and COVID-19 patients kicked-off.
AVATR has been selected as one of the 16 "Game Changers" of the COVID-X EU-funded project (https://www.covid-x.eu/game-changers/).
Imperial College Healthcare NHS Trust - AVATR demonstrator for weight loss management.
Barts Hospital NHS - AVATR demonstrator for cardiac rehabilitation.
Leeds Teaching Hospitals - patients onboarded for obesity and atrial fib programme.
AVATR has been selected for participating to the acceleration programme SPIN, arranged by MISE (Italian Ministry for Innovation), and developed by the ELITE network (https://www.elite-network.com/)
InCor HyperTension Medical Study kick off (São Paulo).
AVATR srl is technically supporting Inavya Ventures to launch multiple trials of AVATR technology in multiple countries: Brazil, Singapore, UK and Germany.
AVATR srl won a R&D project funded by Calabria Region to support the improvement of the AVATR technology and its launch into the Italian market.
AVATR srl is founded by Alessio Gugliotta and Antonio Violi to improve and launch AVATR technology in Italy.
AVATR is a CE Marked medical device.
Inavya Ventures takes part in the Mayor of London’s TechInvest AI pitch, with a view to expand AVATR’s potential into the Smart Cities arena.
The first prototype of AVATR utilising data fromthe SpyderPro system is brought online.
The potential of AVATR to revolutionise healthcare, and doctor/patient relationships is featured in Forbes Magazine.
The UK Government’s Department for International Trade selects Inavya Ventures as one of the eleven Tech Superstars to highlight London-based healthcare technology in Singapore.
The AVATR Trademark is registered within the EU.
With a focus on precision medicine, Inavya Ventures establishes a collaboration agreement with the medical team behind SpyderPro - a medical-grade, wireless ECG monitoring system developed in association with the NationalHeart Centre Singapore.
A Newton Fund R&D grant is awarded to Inavya Ventures to develop and integrate AVATR into a Future Smart Cities project with the city of São Paolo - in partnership with Future Cities Catapult, Space Syntax Ltd., Industrial-I and Brazilian ICT research agency, CPQD.
AVATR is certified by the European Commission’s High-Level Expert Group on Key Enabling Technologies as ‘Technology Readiness Level 7’.
Alessio Gugliotta (AVATR srl founder) and Marko Vujasinovic (main technical lead of AVATR srl) make a technical breakthrough with a unique backend prototype (semantic store and related ontologies) that will become the ‘brain’ that powers AVATR.
Inavya Ventures Ltd is invited to join a UK Government Trade Mission to Singapore, where AVATR’s AI and Machine Learning technology is featured as a novel innovation with the global healthcare, retail and education markets.
Alessio Gugliotta (AVATR srl founder) and Marko Vujasinovic (main technical lead of AVATR srl) join an InnovateUK R&D grant awarded to Inavya Ventures to support the creation of a ‘quantified self’ technology.
AVATR is a CE Marked medical device
'AVATR Technology' is licensed by Inavya Ventures Ltd to Avatr srl
All rights reserved. © Avatr srl 2019.
Reserved area